• Common (>10% users):

  • Sulfur / egg-like burp or breath — characteristic, dose-dependent, especially at >1200 mg empty stomach. Reduced by taking with food, splitting doses, or switching to enteric-coated form.
  • Mild GI upset / nausea — usually at higher doses on empty stomach.

• Less common (1-10%):

  • Headache (mild)
  • Diarrhea / loose stool (typically transient, dose-related)
  • Skin rash (mild; rare in oral form, more common in IV)

• Rare-serious (<1% but worth knowing):

  • Anaphylactoid reaction (IV form mainly): Histamine-release reaction with rash, bronchospasm, hypotension during IV administration. Almost exclusively IV. Oral NAC has near-zero risk of this.
  • Paradoxical bronchospasm (asthmatics, mainly inhaled form): Mucomyst inhalation can trigger acute bronchospasm in some asthmatics. Pre-treat with bronchodilator. Oral form has minimal asthma risk; some asthma patients report oral NAC reduces exacerbations (mucolytic + antioxidant).
  • Hypotension at very high doses combined with nitroglycerin or other nitrate vasodilators: Real interaction (see drug interactions). Sub-clinical at supplement doses unless on nitrates.
  • Theoretical bleeding risk with anticoagulants: NAC has mild antiplatelet activity in vitro. No bleeding events documented at supplement doses.
  • Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis: Single case reports, extremely rare, IV form. Not a routine concern at oral supplement doses.

• Specific watch periods: None standard. Asthmatics starting oral NAC for the first time should monitor for any breathing change in the first 1-2 weeks (very low probability of bronchospasm but worth noting).

• Pregnancy / lactation: Used clinically in pregnancy (paracetamol overdose treatment in pregnant women is standard). FDA Pregnancy Category B. No teratogenicity signal. Lactation data limited; generally considered safe.

• Long-term safety: Multiple human trials at 1200-2400 mg/day for 6-24 months show no chronic toxicity signal. COPD patients have used 600 mg BID for years. Maximum-tested daily dose in humans without serious adverse events: 8 g/day short-term. Practical chronic ceiling: 2400 mg/day for routine use; 4000 mg/day for short rescue periods.

Upper safe intake:

• No formal NOAEL / tolerable upper intake established by EFSA/FDA (it's a drug, not a nutrient).
• 2400 mg/day chronic = clinical OCD trial standard, well-tolerated.
• 4000 mg/day = used in TBI rescue protocol for ~4 days, well-tolerated short-term.
• 8000 mg/day = used in some IV paracetamol loading regimens, short-term clinical use only.